Alex Forrest Hay
About Alex Forrest Hay
Professional Experience in Proteomics, Metabolomics, and Genomics
Alex Forrest-Hay brings 23 years of experience in the fields of proteomics, metabolomics, and genomics. His career includes significant roles at companies like Alamar Biosciences, Seer Bio, Metabolon, Nightingale Health, and Affymetrix. Throughout his professional journey, Alex has consistently demonstrated expertise in commercial rollouts, business development, and clinical assay development.
VP of Sales at Alamar Biosciences
Alex Forrest-Hay joined Alamar Biosciences as the Vice President of Sales in September 2022. In this role, he leverages his extensive experience in the life sciences industry to drive sales and expand the company's market presence. His prior accomplishments include leading successful commercial rollouts and securing significant deals in the sector.
Leadership Roles at Seer Bio and Metabolon
Before joining Alamar Biosciences, Alex Forrest-Hay held the position of VP of Sales at Seer Bio, where he led the commercial rollout of the nanoparticle-based Proteograph proteomics technology. Prior to Seer Bio, he spent five years in the metabolomics sector as VP of Population Health at Metabolon and Head of US Business at Nightingale Health. These roles involved driving business growth and enhancing market strategies.
Key Contributions at Affymetrix and Beckman Coulter
During his nine years at Affymetrix, Alex Forrest-Hay was instrumental in closing multi-million dollar deals with the Million Veterans Program and the UKBiobank. He also developed and launched clinical RNA biomarker assays for various cancers. Prior to Affymetrix, he was a Genomics Specialist at Beckman Coulter for seven years, where he developed clinical genomics assays and supported DNA sequencing advancements.
Educational Background in Molecular Biology
Alex Forrest-Hay holds a BSc Hons Degree in Molecular Biology from the University of East Anglia and a Higher National Diploma in Applied Biology from the University of the West of England. His academic background laid the foundation for his career in the life sciences industry, where he has made significant contributions to research and commercial developments.